Cardiol Therapeutics Inc. CRDL

Cardiol Therapeutics reports that 110 patients have been enrolled in the Phase III MAVERIC trial as of Sept. 23, 2026, ahead of the original end‑Sept target. A blinded review showing fewer recurrences prompted plans to expand enrollment to up to 150 to preserve statistical power and strengthen CardiolRx’s efficacy assessment in recurrent pericarditis. Topline results are now expected in mid‑2027, versus prior guidance of early 2027. The company says existing capital funds MAVERIC through completion, with a cash runway into Q1 2028. MAVERIC is a randomized, double‑blind, placebo‑controlled study using time to first recurrence as the primary endpoint. Cardiol also markets other programs, including CRD‑38, for inflammatory heart disease. Mid-2027 topline results after expanding MAVERIC to 150 patients, with funding through Q1 2028.

Cardiol Therapeutics Inc. receives over USD $7 million in proceeds from warrant exercises. The capital infusion strengthens the company's cash position to support ongoing biotech operations and development.

Cardiol Therapeutics files US$150 million preliminary base shelf prospectus including additional disclosures after Ontario Securities Commission review. Filing enables potential capital raise impacting financial resources and operations.

Cardiol Therapeutics advances CardiolRx into pivotal Phase III trial targeting pericarditis. Advancing CardiolRx into Phase III trial constitutes major clinical development milestone with potential to alter company trajectory.

Cardiol Therapeutics published Phase II clinical data on its recurrent pericarditis treatment in the Journal of the American Heart Association. Positive Phase II data publication in a top journal strengthens clinical credibility and can drive investor sentiment plus partnership interest for CRDL.

Cardiol Therapeutics publishes Phase II Recurrent Pericarditis data in the Journal of the American Heart Association. Phase II data publication in major journal signals strong clinical progress likely to lift CRDL visibility and investor sentiment.

Investors watch Cardiol Therapeutics (TSE:CRDL) closely due to its high cash burn rate, short financial runway of about one year, and potential need for dilutive funding amid ongoing clinical trials. Cash burn concerns could pressure financial performance and require fundraising, moderately impacting investor sentiment and operations.

Cardiol Therapeutics Inc. (CRDL) announces acceptance of Phase II MAvERIC trial results for publication in the Journal of the American Heart Association, highlighting positive outcomes in heart failure treatment. Publication of Phase II results in a prestigious journal validates the drug candidate, enhances credibility, and likely boosts investor sentiment and stock performance.

Cardiol Therapeutics' Phase II MAvERIC results accepted for publication in the Journal of the American Heart Association. Journal acceptance for Phase II data may moderately boost credibility and near-term sentiment without altering core trajectory.

Cardiol Therapeutics Inc. (CRDL) shares rise in US premarket trading after expanding its Phase 3 Maveric trial to include seven additional clinical centers in the U.S. Expanding Phase 3 trial sites accelerates enrollment and timelines for potential drug approval, significantly boosting development prospects and investor sentiment.

Cardiol Therapeutics expands U.S. MAVERIC Phase III trial network to meet growing interest in the pivotal program. Expanding Phase III trial sites accelerates patient enrollment and bolsters path to potential approval.

Cardiol Therapeutics expands U.S. MAVERIC Phase III trial network to meet rising interest in the pivotal program. MAVERIC Phase III network expansion advances pivotal clinical testing and supports regulatory progress for Cardiol.

Cardiol Therapeutics Inc. (CRDL) CEO announces Phase III MAVERIC trial nears full enrollment, with CardiolRx demonstrating promise in treating myocarditis. Phase III trial nearing enrollment and positive myocarditis data represent major clinical milestones that could drive regulatory approval and boost stock performance.

Cardiol Therapeutics Inc. (CRDL) will highlight its MAVERIC Phase III trial and recently published ARCHER results in a live interview with Barchart. Highlighting Phase III MAVERIC trial and recent ARCHER results in an interview may moderately influence investor sentiment and market performance.

Cardiol Therapeutics Inc. (CRDL) narrowed its fiscal 2025 loss and announced it is now fully funded through completion of the MAVERIC trial. Narrowed fiscal loss and full funding through MAVERIC trial completion reduce financial risk and enable key clinical progress, significantly boosting investor sentiment and trajectory.

Cardiol Therapeutics announced its year-end 2025 operational update, detailing progress in clinical trials for CardiolRx in heart failure and pericarditis, financial position with cash runway into 2026, upcoming Phase II Mazime trial data readout, and strategic initiatives including potential partnerships. Year-end update covers pipeline advancements and financial stability with moderate potential to influence investor sentiment and near-term stock performance.

Cardiol Therapeutics presented the Phase III MAVERIC clinical trial timeline for lead candidate CardiolRx at the TD Cowen Healthcare Conference. Phase III timeline update for CardiolRx advances key drug toward potential approval, significantly influencing investor sentiment and company trajectory.

Cardiol Therapeutics Inc. announced the publication of results from its ARCHER Phase II study in the ESC Heart Failure journal. The study evaluated the efficacy and safety of Cardiol's lead product, CardiolRx, in patients with heart failure and reduced ejection fraction. Findings demonstrated significant improvements in clinical outcomes, supporting the potential of CardiolRx as a treatment option in this patient population. The publication is expected to enhance the company's visibility and credibility in the cardiovascular space. The publication of positive Phase II study results is likely to significantly impact Cardiol Therapeutics' market position and investor sentiment.

Cardiol Therapeutics Inc. has successfully closed a bought deal financing, raising gross proceeds of $14.85 million following the full exercise of the over-allotment option. This financing is expected to support the company's ongoing development initiatives. The financing will provide necessary capital for development, potentially influencing financial performance and product innovation.

Cardiol Therapeutics Inc. has announced a bought deal financing arrangement expected to generate gross proceeds of $13.5 million. The financing will be conducted through the issuance of units, with each unit consisting of one common share and one-half of a common share purchase warrant. The company plans to use the proceeds for general corporate purposes and to advance its clinical programs. The financing will provide necessary capital to support clinical programs, which may influence future financial performance.

Cardiol Therapeutics Inc. has announced a bought deal financing arrangement expected to generate gross proceeds of $13.5 million. The financing will involve the issuance of common shares at a price of $1.50 per share, with the underwriters granted an option to purchase additional shares. The funds raised are intended to support the company's ongoing clinical development programs and general corporate purposes. The financing will provide necessary capital for clinical development, potentially influencing future financial performance.

Cardiol Therapeutics Inc. has reached a significant milestone by enrolling 50% of patients in its pivotal Phase III MAVERIC trial, which focuses on recurrent pericarditis. This trial aims to evaluate the efficacy and safety of Cardiol's lead product candidate, CardiolRx, in treating this condition. The company is optimistic about the trial's progress and its potential to address unmet medical needs in recurrent pericarditis. Achieving the 50% enrollment milestone in a pivotal trial is a significant step that could enhance Cardiol's market position and investor sentiment.

Analysts predict that Cardiol Therapeutics Inc. (TSE:CRDL) will reach breakeven soon, driven by advancements in its clinical programs and potential market opportunities. The company is focused on developing innovative therapies for cardiovascular diseases, which could enhance its financial outlook. Investors are optimistic about the company's trajectory as it navigates through its current phase of growth. The expectation of reaching breakeven indicates a moderately noticeable influence on the company's financial performance and market sentiment.

New data from the Phase II ARCHER trial indicate that CardiolRx(TM) significantly improves heart structure in patients with acute myocarditis. This finding supports the potential for Cardiol Therapeutics Inc. to expand its treatment applications across various inflammatory cardiac conditions, enhancing its therapeutic portfolio and market position. The trial results suggest a significant advancement in treatment options for inflammatory cardiac conditions, potentially altering the company's trajectory and investor sentiment.

Cardiol Therapeutics Inc. has received a U.S. patent allowance that provides broad protection for its heart drugs, extending coverage until late 2040. This patent is expected to enhance the company's competitive position in the market and support its ongoing development of innovative therapies for heart conditions. The patent allowance significantly strengthens Cardiol's market position and could lead to major strategic advantages in product development and investor sentiment.

Cardiol Therapeutics Inc. announced that results from its Phase II ARCHER trial will be presented at the upcoming European Society of Cardiology Scientific Meeting focused on myocardial and pericardial diseases. This presentation is expected to highlight the company's advancements in treating heart conditions. The presentation of Phase II trial results at a significant scientific meeting could significantly influence investor sentiment and the company's future trajectory.

Cardiol Therapeutics Inc. (CRDL) is highlighted among TSX penny stocks to watch in October 2025 due to its innovative approaches in cardiovascular therapeutics and potential market opportunities. The company is focusing on advancing its product pipeline and expanding its market presence, which could attract investor interest. Recent developments and strategic initiatives are expected to enhance its competitive positioning in the biotech sector. Significant strategic moves and product advancements are likely to alter the company's trajectory and investor sentiment.

Cardiol Therapeutics Inc. has successfully completed a financing round, raising US$11.4 million, which will extend its cash runway into the third quarter of 2027. This funding is expected to support the company's ongoing development efforts and operational needs. The financing significantly enhances Cardiol's financial stability and operational capacity, likely influencing its strategic initiatives and market positioning.

Cardiol Therapeutics Inc. has secured US$11 million in financing, which will extend its cash runway into the third quarter of 2027. This funding is expected to support the company's ongoing development efforts and operational needs. The financing significantly enhances Cardiol's financial stability and operational capacity, potentially impacting its strategic initiatives and market positioning.

Cardiol Therapeutics Inc. is highlighted among five small drug stocks poised for potential growth as the pharmaceutical industry shows signs of recovery. The article emphasizes the company's focus on innovative therapies for heart diseases, which may benefit from the overall positive market sentiment and increased investment in the biotech sector. Analysts suggest that Cardiol's strategic initiatives and product pipeline could position it favorably in a recovering market, attracting investor interest. The company's focus on innovative therapies and the industry's recovery may moderately influence its market performance.